Methotrexate BAFFles anti-drug antibodies

Methotrexate BAFFles anti-drug antibodies

Combining TNF inhibition with methotrexate treatment is an effective therapeutic approach for patients with rheumatoid arthritis and reduces the likelihood of the patient developing ‘resistance’ to the TNF inhibitor. But how does methotrexate suppress the production of anti-drug antibodies and how c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Rheumatology 2018-09, Vol.14 (9), p.505-506
1. Verfasser: Cronstein, Bruce N.
Format: Artikel
Sprache:eng
Schlagworte:
692/4023/1670/498
692/698/1543/1565/1597/40
692/698/1543/1565/1597/554
692/700/565/1331
692/700/565/1436/1437
Antiarthritic agents
Antibodies
Antineoplastic agents
Arthritis
B cells
Biological products
Biopharmaceuticals
Development and progression
Drug therapy
Glycoconjugates
Health aspects
Immunization
Medicine
Medicine & Public Health
Methotrexate
News & Views
news-and-views
Patient outcomes
Patients
Rheumatoid arthritis
Rheumatoid factor
Rheumatology
Tumor necrosis factor
Universities and colleges
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Combining TNF inhibition with methotrexate treatment is an effective therapeutic approach for patients with rheumatoid arthritis and reduces the likelihood of the patient developing ‘resistance’ to the TNF inhibitor. But how does methotrexate suppress the production of anti-drug antibodies and how can we tell which patients will develop resistance?
ISSN:1759-4790
1759-4804
DOI:10.1038/s41584-018-0064-y